Connection
Jeffrey Bennett to Recombinant Fusion Proteins
This is a "connection" page, showing publications Jeffrey Bennett has written about Recombinant Fusion Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.099 |
|
|
|
-
Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J. ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J Neurol Sci. 2015 Apr 15; 351(1-2):174-178.
Score: 0.099